vTv Therapeutics Inc. (VTVT) Given Consensus Recommendation of “Buy” by Analysts

vTv Therapeutics Inc. (NASDAQ:VTVT) has earned an average rating of “Buy” from the six analysts that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $16.00.

VTVT has been the subject of several recent research reports. Citigroup reissued an “add” rating on shares of vTv Therapeutics in a research report on Wednesday, November 8th. Zacks Investment Research raised vTv Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research report on Thursday, August 24th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $12.00 price target on shares of vTv Therapeutics in a research report on Friday, November 3rd.

vTv Therapeutics (VTVT) opened at $4.20 on Friday. vTv Therapeutics has a 1 year low of $3.57 and a 1 year high of $8.09.

A number of large investors have recently made changes to their positions in VTVT. Ameriprise Financial Inc. increased its position in vTv Therapeutics by 62.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 264,214 shares of the biotechnology company’s stock valued at $1,313,000 after buying an additional 101,850 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in vTv Therapeutics during the 3rd quarter valued at about $481,000. Renaissance Technologies LLC increased its position in vTv Therapeutics by 4.8% during the 1st quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock valued at $418,000 after buying an additional 2,900 shares in the last quarter. State Street Corp grew its stake in vTv Therapeutics by 2.1% during the 2nd quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after purchasing an additional 1,976 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in vTv Therapeutics by 6.1% during the 1st quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 1,305 shares during the last quarter. 10.42% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “vTv Therapeutics Inc. (VTVT) Given Consensus Recommendation of “Buy” by Analysts” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/03/vtv-therapeutics-inc-vtvt-given-consensus-recommendation-of-buy-by-analysts-2.html.

About vTv Therapeutics

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Analyst Recommendations for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply